From WikiProjectMed
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetlymphotoxin alpha
Clinical data
Other namesMLTA3698A
ATC code
  • none
CAS Number
  • none
Chemical and physical data
Molar mass144716.68 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Pateclizumab (MLTA3698A) is an immunomodulator. It binds to lymphotoxin alpha.[1][2][3][4][5][6]

This drug was developed by Genentech/Roche.


  1. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).[dead link]
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab, American Medical Association.
  3. ^ Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC (October 2014). "Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)". Arthritis Res. Ther. 16 (5): 467. doi:10.1186/s13075-014-0467-3. PMC 4243296. PMID 25359150.
  4. ^ Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC (January 2012). "Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial". Arthritis Res. Ther. 14 (1): R6. doi:10.1186/ar3554. PMC 3392792. PMID 22225620.
  5. ^ Wang H, Schuetz C, Arima A, Chihaya Y, Weinbauer GF, Habermann G, Xiao J, Woods C, Grogan J, Gelzleichter T, Cain G (August 2016). "Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates". Reprod. Toxicol. 63: 82–95. doi:10.1016/j.reprotox.2016.05.014. PMID 27211603.
  6. ^ Hirose T, Fukuma Y, Takeshita A, Nishida K (June 2018). "The role of lymphotoxin-α in rheumatoid arthritis". Inflamm. Res. 67 (6): 495–501. doi:10.1007/s00011-018-1139-6. PMID 29541795. S2CID 3910200.